MEDIUM confidence: 100% data completeness, but the composite (46) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-12.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Net insider -$20.1M over 180 days (0 open-market buys, 30 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Avg target $144 (last qtr, 10 analysts) → $142 (last mo, 5) (-1.3%).
Buy-rated share 75% → 76% over ~3 months (+1pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $-7.25 | $-6.75 | +6.9% |
| May 2026 | $1.91 | $2.03 | +6.3% |
| Feb 2026 | $1.81 | $1.86 | +2.8% |
| Oct 2025 | $2.13 | $2.47 | +16.0% |
| Aug 2025 | $1.96 | $2.01 | +2.6% |
| Apr 2025 | $1.78 | $1.81 | +1.7% |
| Feb 2025 | $1.74 | $1.90 | +9.2% |
| Nov 2024 | $1.53 | $2.02 | +32.0% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $27.3B— | $27.3B-0.1% | $27.1B-0.6% | $28.8B+6.0% | $29.4B+2.4% |
| EPS (dil.) | $4.93— | $3.64-26.2% | $4.50+23.6% | $0.38-91.6% | $6.78+1684.2% |
| Free Cash Flow | $10.8B— | $8.3B-22.8% | $7.4B-11.1% | $10.3B+38.9% | $9.5B-8.2% |
| Gross Margin | 75.8% | 79.3%+3.4pp | 76.0%-3.2pp | 78.3%+2.2pp | 78.8%+0.6pp |
| Operating Margin | 36.3% | 26.9%-9.5pp | 28.0%+1.2pp | 5.8%-22.3pp | 39.7%+34.0pp |
| Net Margin | 22.8% | 16.8%-6.0pp | 20.9%+4.1pp | 1.7%-19.2pp | 28.9%+27.2pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 6.3%/yr (revenue basis).
Base free cash flow $9.1B (avg FY2023–FY2025; latest year $9.5B) · equity value $170.2B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 46 for Gilead Sciences indicates a neutral outlook, with the stock's long-term and short-term scores relatively aligned. The stock scores high on growth, driven by a notable 1700% EPS growth, but is dragged down by its value category, which is impacted by a high EV/EBITDA of 303.8. The stock's momentum is moderate, with a 12-month return of 14.4%, and its profitability is mixed, with a high gross margin but negative ROE and operating margin. Overall, Gilead Sciences trades at a premium, exhibiting strong growth but struggling with profitability and value metrics.